NCT04822181semaglutidesteatohepatitisliver fibrosis
… for its potential to treat MASH in the ongoing ESSENCE trial ( NCT04822181).Methods ESSENCE, a phase 3 trial involving 1200 participants w…
5,089articles mentioning funders
9,137funder mentions
3,238distinct funders extracted
0%of mentions human-reviewed
All extracted funders
Showing 601–660 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.
Corrective Services1Crown Agents1DIrectory of RAdiotherapy Centres1DRF1DSMB/Advisory Board1Defense Advanced Research Projects Agency1Defense Health Agency1Defense Health Program1Dutch Health Insurance Act1Dying Matters1ECDC1EMLSEN1EPSRC1ESSA1European Medicines Authority1European Psychiatric Association1Fedris1Food and Drug Administration-guided1Foundation for the Accreditation of Cellular Therapy1GMKA1General Pharmaceutical Council1Genomics Clinical Reference Group1German Clinical Trials Registry1Gilead1HQIP1Harkness Fellowship1Health NGOs1Health Policy Council1Health Resources and Services Administration1Horizon 2020 research and innovation programme1ICRS-FIFA-Aspetar1IFSPT1IHIO1IMF1IPA1IREC1ISPs1ITMCTR20250013111JSTOR1Japanese universal health insurance system1KMFDS1Liminal BioSciences1Lothian NHS Board1MCPs1METIS Innovative1MSF-PEWS1Medicare programme1MoPH1NCDB1NCT014516581NCT035073091NCT055114281NCT055903901NCT058099341NCT059958471NCT063883041NCT070367831NHS Greater Manchester1NHS Hampshire and Isle of Wight1NHS ambulance Trust1
Articles mentioning funders
5,089 articles · page 369 of 425NHSchronic liver disease (CLD)Metabolic dysfunction-associated steatotic liver disease (MASLD)MASLD
…ancet commission prioritises earlier diagnosis of fibrosis with NHS community pilots underway. We aimed to evaluate the performance…
NCT04526665PBCElafibranor
…s are common symptoms in PBC. In the phase III ELATIVE® trial ( NCT04526665), elafibranor significantly improved biomarkers of cholestasis …
NCT04526665osteoporosisPBCelafibranorosteopenia
…iomarkers assessed to Week 52 in the phase III ELATIVE® trial ( NCT04526665).Patients (N=161) were randomized 2:1 to elafibranor 80 mg or p…
NCT04526665ElafibranorPBCFibrosis
…LF]) and biochemical markers in patients with PBC in ELATIVE® ( NCT04526665) to Week 104; NITs are also stratified by disease stage.Proport…
National Institute for Health and Care Excellenceliver cancerAFPPBCAIHSwansea Bay University Health Boardliver diseaseHCCPSCcurative treatment+2 more
…st risk to develop HCC, British Society of Gastroenterology and National Institute for Health and Care Excellence guidelines recommend 6-monthly US surveillance with/without AFP…
TrustsHepatocellular carcinomahepatitis BcirrhosisHCCcurative treatmentEuropean Association for the Study of the Liver
… the development of standardised HCC surveillance strategies in Trusts, with dedicated surveillance databases now being created, in ad…
AASLDRifaximinLactulosehepatic encephalopathychronic liver diseaseLOLAliver cirrhosis
…se. 1 The American Association for the Study of Liver Diseases (AASLD) makes a recommendation for IV L-ornithine L-Aspartate (LOLA) t…
TrustDecompensated liver cirrhosisCirrhoSIMhepatic encephalopathydecompensated cirrhosisAcute-on-chronic liver failurespontaneous bacterial peritonitisACLFvariceal bleeding
…rdise early interventions and improve cirrhosis management, our Trust adapted the British Society of Gastroenterology evidence-based …
SLaMceruloplasminCpSouth London and Maudsley NHS Foundation TrustWDSLaMWilson diseaseWilson’s disease
…tric assessment.South London and Maudsley NHS Foundation Trust (SLaM) is an international leader in mental health and is the largest…
Ethics Review Boardbreast cancerKyoto University Central Institutional Review Boardbreast reconstructionJapanese Society of Breast Oncoplastic Surgery
…mission for performance of the study has been obtained from the Ethics Review Board at each participating centre. We plan to disseminate the findin…
EU-trial-number 2023-510186-98VTEMedical Research Ethics Committee Leiden-Den Haag-Delft
…by the Medical Research Ethics Committee Leiden-Den Haag-Delft, EU-trial-number 2023-510186-98. Study results will be disseminated through peer-reviewed journ…